Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis.
Kałwak
K
K
Department of Pediatric Hematology and Oncology, Medical University of Wrocław, 44 Bujwida Street, 50-345 Wrocław, Poland. kk@pedhemat.am.wroc.pl
Ussowicz
M
M
Gorczyńska
E
E
Toporski
J
J
Turkiewicz
D
D
Bogusławska-Jaworska
J
J
Chybicka
A
A
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D008558:Melphalan / Q000627:therapeutic use; D017599:Neuroectodermal Tumors / Q000628:therapy*; D010976:Platelet Count; D011379:Prognosis; D017384:Sequence Deletion; D016896:Treatment Outcome
D007376:Interleukin-2; D002066:Busulfan; D008558:Melphalan